The prevalence of MS increased progressively across HER2 quartiles: 31.30% (Q1), 36.43% (Q2), 50.00% (Q3), and 72.39% (Q4) (<i>p</i> < 0.001). This evidence concerns the gene ERBB2 and myeloid sarcoma.